Skip to main content

Table 3 Comparison of clinical data between the brain injury and the control groups

From: Effect of β2-microglobulin in evaluating the severity and prognosis of brain injury: a clinical study

Category

Brian injury group(n = 54)

Control group (n = 11)

P

Age

47 ± 14

51 ± 14

0.321

 Gender (male = n%)

39 (72%)

6 (54%)

0.200

β2MG before HBOT

2.64 ± 0.79

1.73 ± 0.39

0.001

β2MU before HBOT

6.82 ± 20.2

0.17 ± 0.16

0.006

SCR before HBOT

52 ± 14

64 ± 11

0.016

BUN before HBOT

5.3 ± 2.2

4.3 ± 1.2

0.190

β2MG after 1st course HBOT

2.58 ± 0.76

1.73 ± 0.39

0.002

β2MU after 1st course HBOT

2.07 ± 7.46

0.17 ± 0.16

0.258

SCR after 1st course HBOT

47 ± 16

64 ± 11

0.004

BUN after 1st course HBOT

4.4 ± 1.4

4.3 ± 1.2

0.907

β2MG after 2nd course HBOT

2.14 ± 0.66

1.73 ± 0.39

0.067

β2MU after 2nd course HBOT

0.65 ± 2.09

0.17 ± 0.16

0.308

SCR after 2nd course HBOT

47 ± 15

64 ± 11

0.004

BUN after 2nd course HBOT

4.1 ± 1.3

4.3 ± 1.2

0.715

  1. Comparison of clinical data between the brain injury and the control groups. Continuous variables are expressed as percentage or mean ± standard deviation, categorical variables are showed as percentage(n%). P < 0.05 indicates statistical difference.β2MG, β2-microglobulin (mg/L); β2MU, urineβ2-microglobulin (mg/L); SCR Serum creatinine (μmol/L), BUN Blood urea nitrogen (μmol/L)